临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 30562-34-6

Geldanamycin (NSC 122750)

中文名称:格尔德霉素
CAS号:30562-34-6
分子式: C29H40N2O9 分子量: 560.64
产品形式: free base
研发状态: Completed
研发用途: Unspecified Adult Solid Tumor Protocol Specific
研究机构: Cancer Research UK; National Cancer Institute (NCI)
研发日期: Aug-98
研发阶段: Phase 1
Geldanamycin (NSC 122750) is a natural existing HSP90 inhibitor with Kd of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association. Geldanamycin attenuates virus infection-induced ALI (acute lung injury)/ARDS (acute respiratory distress syndrome) by reducing the host's inflammatory responses.

CAS: 3056-17-5

Stavudine (d4T)

中文名称:司他夫定
CAS号:3056-17-5
分子式: C10H12N2O4 分子量: 224.21
产品形式: free base
研发状态: Completed
研发用途: HIV
研究机构: SEARCH Research Foundation; University of Hawaii
研发日期: May-10
研发阶段: --
Stavudine (d4T, BMY-27857, Sanilvudine, NSC 163661) is a nucleoside analog reverse transcriptase inhibitor (NARTI) active against HIV.

CAS: 30516-87-1

Zidovudine

中文名称:齐多夫定
CAS号:30516-87-1
分子式: C10H13N5O4 分子量: 267.24
产品形式: free base
研发状态: Completed
研发用途: HIV Infections
研究机构: University of Cape Town; Wellcome Trust; Médecins Sans Frontières Belgium
研发日期: August 8 2019
研发阶段: Phase 2
Zidovudine (ZDV, Azidothymidine, NSC 602670,Retrovir) is a nucleoside analogue reverse transcriptase inhibitor, used to treat HIV. It could decrease the HDR efficiency and decrease CRISPR-mediated sequence-specific genome knockin events while increaseing knockout efficiency.

CAS: 304-20-1

Hydralazine HCl

中文名称:盐酸肼屈嗪
CAS号:304-20-1
分子式: C8H8N4.HCl 分子量: 196.64
产品形式: Hydrochloride
研发状态: Completed
研发用途: Preeclampsia With Severe Features
研究机构: Ohio State University
研发日期: December 1 2021
研发阶段: --
Hydralazine HCl is a hydrochloride salt of hydralazine, which is a direct-acting smooth muscle relaxant used to treat hypertension by acting as a vasodilator primarily in arteries and arterioles.

CAS: 303149-14-6

HT-2157

CAS号:303149-14-6
分子式: C21H13F3N2O 分子量: 366.34
产品形式: Free base
研发状态: Completed
研发用途: Healthy Volunteers (Part 1); Major Depressive Disorder (Part 2)
研究机构: Dart NeuroScience LLC
研发日期: Jul-11
研发阶段: Phase 1 : Phase 2
HT-2157 (SNAP37889) is a selective, high-affinity, competitive antagonist of galanin-3 receptor (Gal3).

CAS: 302962-49-8

Dasatinib (BMS-354825)

中文名称:达沙替尼
CAS号:302962-49-8
分子式: C22H26ClN7O2S 分子量: 488.01
产品形式: free base
研发状态: Recruiting
研发用途: Recent HIV-1 Infection
研究机构: Eva Bonfill; Institut d''Investigacions Biomèdiques August Pi i Sunyer
研发日期: January 26 2024
研发阶段: Phase 2
Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.